Novel ALK Inhibitors in Clinical Use and Development

Authors

Chaitanya Iragavarapu, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA. Iragavarapuc@wcmc.com.
Milaim Mustafa, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA. mmustafa@une.edu.
Akintunde Akinleye, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA. docakin@gmail.com.
Muhammad Furqan, Department of Medicine, Division of Hematology and Oncology, University of Iowa Carver College of Medicine, Iowa City, IA, 52242, USA. dr_furqandow@yahoo.com.
Varun Mittal, Department of Medicine, Division of Hematology/Oncology, Albert Einstein Medical Center, Philadelphia, PA, 19141, USA. varun.doc7@gmail.com.
Shundong Cang, Department of Oncology, Henan Province People's Hospital|, Zhengzhou University, Zhengzhou, China. cangshundong@163.com.
Delong Liu, Henan Cancer Hospital, Zhengzhou University, Zhengzhou, China. delong_liu@nymc.edu.

Author Type(s)

Faculty

DOI

10.1186/s13045-015-0122-8

Journal Title

Journal of Hematology & Oncology

First Page

17

Document Type

Article

Publication Date

2-27-2015

Abstract

Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in anaplastic large cell lymphoma (ALCL). ALK mutations have also been implicated in the pathogenesis of non-small cell lung cancer (NSCLC) and other solid tumors. Multiple small molecule inhibitors with activity against ALK and related oncoproteins are under clinical development. Two of them, crizotinib and ceritinib, have been approved by FDA for treatment of locally advanced and metastatic NSCLC. More agents (alectinib, ASP3026, X396) with improved safety, selectivity, and potency are in the pipeline. Dual inhibitors targeting ALK and EGFRm (AP26113), TRK (TSR011), FAK (CEP-37440), or ROS1 (RXDX-101, PF-06463922) are under active clinical development.

Recommended Citation

Iragavarapu, C., Mustafa, M., Akinleye, A., Furqan, M., Mittal, V., Cang, S., & Liu, D. (2015). Novel ALK Inhibitors in Clinical Use and Development. Journal of Hematology & Oncology, 8, 17. https://doi.org/10.1186/s13045-015-0122-8